Menarini Group Unveils New Insights on ELZONRIS at ASH 2025 Annual Meeting
Menarini Group Unveils New Insights on ELZONRIS at ASH 2025 Annual Meeting
Menarini Group, a leading global pharmaceutical and diagnostic company, in partnership with Stemline Therapeutics, has announced significant new data regarding ELZONRIS® (tagraxofusp-erzs) that will be presented at the 67th Annual Meeting of the American Society of Hematology (ASH) in Orlando from December 6 to 9, 2025. This presentation will include five summaries, notably two oral presentations, shedding light on critical advancements for patients diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Background on BPDCN
BPDCN is a rare and aggressive hematological malignancy that primarily affects the skin, bone marrow, and blood. It can also metastasize to lymph nodes, spleen, liver, and central nervous system. Approximately 85%-90% of BPDCN patients present with skin lesions as the first clinical sign. The global prevalence of this condition stands at roughly 0.4 to 0.5 per 100,000 individuals annually, affecting equally both men and women, though about 75% of cases occur in men with a median age at diagnosis between 60 to 70 years. One distinctive feature of BPDCN cells is their strong expression of the CD123 protein, serving as both a diagnostic marker and a therapeutic target for precision therapies.
Key Presentations and Findings
During the ASH 2025 meeting, the following topics will be elaborated upon:
- - Presentation by Navarro Vicente I: Discussing disease characteristics and immunophenotypic features in 257 BPDCN patients, highlighting essential biomarkers and molecular markers that inform diagnostics and prognostics.
- - Session led by Lane A: Focusing on the results of a triplet therapy combining tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN). This combination has demonstrated both efficacy (high response rates and successful transplants) and tolerability in patients with BPDCN.
- - Investigation by Stein A: Comparing survival outcomes between patients treated with tagraxofusp versus those receiving venetoclax, providing real-world data supporting tagraxofusp's effectiveness.
- - Study by Wang E: Evaluating favorable outcomes, including transplants, in treatment-naive patients with varying skin lesions treated with tagraxofusp.
- - Research by Cho W: Covering the use of tagraxofusp and low-intensity chemotherapy in relapsed or refractory acute myeloid leukemia (AML).
Clinical Significance of ELZONRIS
Approved by the FDA in December 2018, ELZONRIS is indicated for BPDCN treatment in adults and children aged two years and older, marking a significant milestone in targeted therapies for this difficult-to-treat condition. The recent data reinforces the critical role of tagraxofusp in both monotherapy and combination treatments for BPDCN, fostering hopes of expanding its applications to other aggressive hematological malignancies where effective options are urgently needed.
Elcin Barker Ergun, CEO of Menarini Group, stated, "Our commitment to transform the lives of individuals battling hard-to-treat cancers remains unwavering. The data reveals that tagraxofusp plays a crucial role in the treatment of BPDCN and may potentially benefit patients with other aggressive blood disorders."
Commitment to Patient Safety
While presenting ELZONRIS data, Menarini also addresses safety concerns associated with its use. Notable warning includes the risk of capillary leak syndrome, which can be life-threatening. The company emphasizes regular monitoring and necessary precautions during treatment. Patients are advised to be aware of potential side effects, including hypersensitivity reactions and hepatotoxicity.
Conclusion
The Menarini Group and Stemline Therapeutics prepare for an impactful ASH 2025 presentation, heralding advancements in BPDNC treatments and underlining their commitment to meeting pressing unmet medical needs in hematology. Through ELZONRIS, the collaboration aims to bring transformative therapies to patients who need them the most, ultimately enhancing care and outcomes for individuals facing aggressive blood cancers.
For more detailed information about ELZONRIS and its implications, visit www.elzonris.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.